Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIK1 | P39086 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.53 |
| ▸ | CA2 | P00918 | 1/20 | 0.53 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | CPB2 | Q96IY4 | 2/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.50 |
| ▸ | PTGES | O14684 | 2/20 | 0.49 |
| ▸ | ALOX5 | P09917 | 2/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29650381 | 0.98 | GRIK1 (0.56) | GRIK1CYP1A2CA2MAPK1CPB2 | |
| SCHEMBL11050992 | 0.98 | GRIK1 (0.56) | GRIK1CYP1A2CA2MAPK1CPB2 | |
| SCHEMBL1026190 | 0.95 | GRIK1 (0.64) | GRIK1CYP1A2CA2MAPK1CPB2 | |
| SCHEMBL5510828 | 0.88 | GRIK1 (0.56) | GRIK1CPB2FOLH1PTGESALOX5 | |
| SCHEMBL585398 | 0.87 | CYP1A2 (0.59) | GRIK1CYP1A2CA2MAPK1PPARG | |
| SCHEMBL10869949 | 0.87 | GRIK1 (0.55) | GRIK1CPB2PTGESALOX5PPARG | |
| SCHEMBL8845789 | 0.87 | PTGES (0.56) | GRIK1CA2MAPK1CPB2PTGES | |
| SCHEMBL11305180 | 0.87 | GRIK1 (0.55) | GRIK1CPB2PTGESALOX5PPARG | |
| SCHEMBL355603 | 0.87 | GRIK1 (0.55) | GRIK1CPB2PTGESALOX5PPARG | |
| SCHEMBL5385323 | 0.87 | GRIK1 (0.55) | GRIK1CPB2PTGESALOX5PPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2072083-B1 | Utilisation of 2.4'-dimethyl-propiophenon as an aroma | SYMRISE AG (DE) | 2012-02-15 | — | — | EP | claimed |
| US-20090162308-A1 | USE OF 2,4'-DIMETHYLPROPIOPHENONE AS A FRAGRANCE SUBSTANCE | SYMRISE GMBH & CO. KG (DE) | 2009-06-25 | — | — | US | claimed |
| US-20090162308-A1 | USE OF 2,4'-DIMETHYLPROPIOPHENONE AS A FRAGRANCE SUBSTANCE | SYMRISE GMBH & CO. KG (DE) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090162308-A1 | USE OF 2,4'-DIMETHYLPROPIOPHENONE AS A FRAGRANCE SUBSTANCE | CYP1B1, CYP4A22, ROS1 | GRIK1 3356/4885CYP1A2 7/4885CA2 4350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.